ZANTAC 25
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZANTAC 25 (ZANTAC 25).
Competitive histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking H2 receptors on parietal cells, reducing both basal and stimulated acid production.
| Metabolism | Primarily hepatic metabolism via N-oxidation, S-oxidation, and N-demethylation; minor renal excretion of unchanged drug. |
| Excretion | Renal: 70% unchanged via tubular secretion; fecal: 30% as metabolites (N-oxide, S-oxide, desmethyl). |
| Half-life | Terminal elimination half-life: 2.5-3.0 hours (normal renal function); prolonged to 4-5 hours in elderly and up to 6-8 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | ~15% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 1.0-1.5 L/kg (suggests extensive extravascular distribution; higher in elderly due to decreased lean body mass). |
| Bioavailability | Oral: 50-60% (first-pass metabolism); IM: 90-100%; IV: 100%. |
| Onset of Action | Oral: 30-60 minutes (peak effect at 1-2 hours); IV: within minutes (peak effect at 15-30 minutes). |
| Duration of Action | Single oral dose: 4-8 hours (acid suppression); continuous IV infusion: duration correlates with infusion rate. |
Ranitidine 150 mg orally twice daily or 50 mg intravenously every 6-8 hours.
| Dosage form | TABLET, EFFERVESCENT |
| Renal impairment | CrCl 30-50 mL/min: 75 mg orally every 12 hours; CrCl 15-30 mL/min: 50 mg orally every 12 hours; CrCl <15 mL/min: 50 mg orally every 24 hours. |
| Liver impairment | Child-Pugh Class B or C: Reduce dose by 50% or extend dosing interval. |
| Pediatric use | Weight-based: 2-4 mg/kg orally twice daily; IV: 1-2 mg/kg every 6-8 hours (max 50 mg per dose). |
| Geriatric use | No specific dose adjustment, but consider age-related renal impairment; use lower end of dosing range. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZANTAC 25 (ZANTAC 25).
| Breastfeeding | Excreted into breast milk; M/P ratio approximately 1.92. Concentrations are lower than infant therapeutic doses. Considered compatible with breastfeeding; monitor infant for irritability, sedation, or gastrointestinal effects. |
| Teratogenic Risk | Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data do not indicate increased risk of major malformations. Caution in first trimester; theoretical risk of histamine receptor blockade affecting fetal development. Avoid high doses near term due to potential for adverse neonatal effects. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to ranitidine or any component of the formulation","Acute porphyria (may precipitate attacks)"]
| Precautions | ["May mask symptoms of gastric malignancy","Reversible confusional states (especially in elderly or renally impaired)","Risk of community-acquired pneumonia (possible association with acid suppression)","Caution in patients with hepatic impairment","Caution in patients with renal impairment (dose adjustment recommended for CrCl <50 mL/min)","Acute porphyria: may precipitate attacks","Possible vitamin B12 deficiency with long-term use","Rebound hypersecretion upon abrupt discontinuation after prolonged therapy"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal renal function and gastrointestinal symptoms. No specific fetal monitoring required; surveillance for adverse effects in pregnancy (e.g., preeclampsia) as per routine obstetric care. |
| Fertility Effects | No significant adverse effects on fertility in human studies. Theoretical anticholinergic effects may impact cervical mucus or sperm function; clinical relevance unlikely. |